Renal denervation in resistant arterial hypertension: Effects on neurohormonal activation and cardiac natriuretic peptides

Renal denervation (RD) is an emerging treatment for resistant arterial hypertension (RAH). RAH is characterized by hyperactivity of catecholaminergic and renin–angiotensin–aldosterone systems (RAAS), with elevated arterial blood pressure and a higher prevalence of cardiovascular overload and remodeling. As renal innervation is involved in sympathetic and RAAS overactivation, RD has the potential to reduce blood pressure by influencing this pathophysiological network [1]. Indeed, RD has been shown to reduce renal norepinephrine spillover [2] and it seems to exert beneficial effects also on cardiac remodeling by reduction of cardiac hypertrophy